Sacituzumab
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan. Sacituzumab govitecan can be used in the field of triple-negative breast cancer[1][2][3][4].
Product Specifications
CAS Number
1796566-95-4
Product Name Alternative
HRS7
UNSPSC
12352203
Target
ADC Antibody; TROP2
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sacituzumab.html
Purity
99.86
Solubility
H2O
Smiles
[Sacituzumab]
Molecular Weight
(145.52 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CD106 / VCAM1 (1.4C3), CF568 conjugate, 0.1mg/mL
Complement C4d (C4D204), CF740 conjugate, 0.1mg/mL
Cytokeratin 8/18 (C-51), CF640R conjugate, 0.1mg/mL
